CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.

For the first time, scientists have successfully used gene-editing technology to eliminate a primary allergy-causing protein in two dogs, Bailey the beagle and her twin Alfie.

CRISPR Therapeutics CRSP incurred second-quarter 2026 loss of 94 cents per share, which was narrower than the Zacks Consensus ...

Scientists at a biotech company have used gene editing to create two hypoallergenic beagles that don't trigger allergies.

CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to ...

A company has created dogs that do not have the main protein that provokes allergies, and hopes to get approval to start ...

The next six months may be decisive for the biotech.

Researchers used CRISPR to remove the CD33 protein from donor stem cells, protecting healthy blood cells from therapies that target leukemia. In a 30-patient trial, the edited cells rebuilt blood ...

The main function of CRISPR-Cas systems is to defend bacteria against various threats, including viruses called ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. A strange thing happened weeks before the ...

Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.